CompletedNCT04293549

An 8-week Follow-up to Evaluate the Renewal of Corneal Nerves Structure and Function in Patients With Neurotrophic Keratopathy Treated With Recombinant Human Nerve Growth Factor (rhNGF) Eyedrops

Studying Neurotrophic keratopathy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
G. d'Annunzio University
Principal Investigator
Leonardo Mastropasqua, Professor
Ophtalmology Clinic, G. d'Annunzio University
Intervention
Cenegermin, recombinant human Nerve Growth Factor (rhNGF) eyedrops(drug)
Enrollment
18 target
Eligibility
All sexes
Timeline
2018 – 2018

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04293549 on ClinicalTrials.gov

Other trials for Neurotrophic keratopathy

Additional recruiting or active studies for the same condition.

See all trials for Neurotrophic keratopathy →

← Back to all trials